Clinical Trials Browser

Phase 2 × Gastroesophageal Cancer × Ramucirumab × Clear all

NCT02317991 2022-07-01

Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer

Phase 2 Completed

65 enrolled 11 charts

Gastrointestinal

Gastroesophageal Cancer